Physician profile
Samuel E Seltzer
NPI 1053379107
$2,752.52
in general payments reported to CMS, 2019-2025
13 companies · $540 in 2025
The $540 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $84.25 · 2021: $692 · 2022: $547 · 2023: $247 · 2024: $492 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,222 · Honoraria: $38.86 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,221.82 |
| Honoraria | $38.86 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,075.25 | 2019-2025 | Clareon, Argos |
| Rxsight INC | $206.30 | 2024-2025 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Johnson & Johnson Surgical Vision, INC. | $123.69 | 2021 | |
| Mallinckrodt Hospital Products INC. | $109.46 | 2021-2022 | |
| Sight Sciences, INC. | $88.26 | 2022 | |
| Novartis Pharmaceuticals Corporation | $38.31 | 2020 | |
| Omeros Corporation | $28.58 | 2019 | |
| Thea Pharma INC. | $24.77 | 2023 | |
| Ocular Therapeutix, INC. | $20.43 | 2025 | Dextenza |
| Harrow Eye, LLC | $19.63 | 2024 | Iheezo |
| Bausch & Lomb Americas INC. | $17.84 | 2024 | Miebo |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Seltzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.